BioPharma Clinical Trials
OncoC4 Doses First Patient in Phase I Trial of neoCD24-Targeting T-Cell Engager ONC-783
— ONC-783 is the first-and-only clinical-stage T-cell engager targeting a cancer-specific glycoform of CD24 (neoCD24) — — Subcutaneous f...
August 19, 2026 | News
Connext Completes Phase 2 Enrollment of CNT201 for Dupuytren’s Contracture
All 56 planned participants enrolled approximately five months after first patient dosing - Topline Phase 2 data expected in late 2026 - Positive d...
August 19, 2026 | News
JW Pharmaceutical’s Epaminurad Shows Statistical Superiority in Phase III Gout Trial
-JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ‘Epaminurad (code name U...
August 18, 2026 | News
AbelZeta Secures US FDA IND Clearance for Bispecific CAR-T Therapy C-CAR039 in Large B-cell Lymphoma
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovati...
August 18, 2026 | News
ArkBio Advances Ziresovir into US Phase II Trial for Severe RSV in Infants
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved ziresovir (AK0529) for a phase II cli...
August 17, 2026 | News
China Approves Geneseeq’s PanTRKare as Companion Diagnostic for VELMARTO
NMPA granted approval to Geneseeq's PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectini...
August 14, 2026 | News
ArkBio’s Long-Acting Influenza Candidate AK0406 Secures IND Approval in China
Shanghai Ark Biopharmaceutical Co., Ltd. announced that the Investigational New Drug (IND) application for AK0406 injection, the company's first long-actin...
August 14, 2026 | News
Asia-Pacific’s Geroscience Paradox: Plenty of Ageing Research, Just Five Clinical Assets
It is not a settled matter. It is a claim that has been made continuously for four years without anyone publishing the test they applied. So we wrote a tes...
August 13, 2026 | Analysis
Datasea Lists NeuroVibe Biofeedback System with US FDA as Class II 510(k)-Exempt Device
Datasea Intelligent Technology Ltd. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company focused on acoustic high-tech and AI multimodal digit...
August 13, 2026 | News
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializin...
August 12, 2026 | News
Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...
August 11, 2026 | News
RiboX Secures FDA IND Clearance for World’s First Circular RNA-Based In Vivo CAR-T Therapy
The FDA IND clearance supports the initiation of RiboX's Phase 1 clinical trial evaluating targeted LNP-delivered circular RNA-based in vivo CAR-T therapy ...
August 10, 2026 | News
Alteogen Signs Up to $365 Million Hybrozyme Licensing Deal for Subcutaneous Biologic
Alteogen grants exclusive rights to develop and commercialize a subcutaneous biologic product using Hybrozyme™-based hyaluronidase ALT-B4 Alteogen...
August 07, 2026 | News
Adneuris Licenses Cebranopadol Rights to Maruishi for Japan and South Korea
Agreement Grants Maruishi Rights for the Development and Commercialization of Cebranopadol for Pain in Japan and South Korea, Marking Adneuris' Second Ex...
August 07, 2026 | News
Most Read
- Can APAC Biomanufacturing Decarbonise Without Pricing Itself Out?
- The Algorithm on the GMP Floor: AI Promises a Smarter Plant. Regulators Demand the Audit Trail.
- APAC's Peptide-Capacity Gamble
- After the Rush: APAC's mRNA and Vaccine Capacity Hangover
- The Biosimilar Race: Factory to the World — or Stuck in the Copycat Economy?
- The Vein-to-Vein Problem: Can APAC's Cold Chain Carry Advanced Therapies?
- Vectors, Plasmids and the CGT Trap: APAC's Cell and Gene Therapy Ambitions Face an Upstream Bottleneck
- Can APAC Build Radioligand Therapy Before the Atoms Decay?
- The Great Biopharma Reset: 50 Developments That Changed Everything in H1 2026
- Beyond the Trial: Can Real-World Evidence Earn Regulatory Trust in APAC?
- Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next
- The Frontier That Won’t Quite Arrive
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
